A diagnostic kit for liver cancer called Jietaisi – being produced by a biomedical company in Taizhou city – was recently approved by the National Medical Products Administration, or NMPA.
The kit was developed by Jiangsu SysDiagno Biotech Co Ltd, located in the Taizhou Medical High-tech Zone in Taizhou city, in East China's Jiangsu province.
Jietaisi assesses the risk of liver cancer by detecting the sugar chains in human serum and helps clinical doctors diagnose liver cancer earlier through big data and artificial intelligence analysis.
The product has become the world's first in vitro diagnostic or IVD product for detecting tumours based on glycomics technology. It's also the first national level innovative medical device product approved for a listing from the Taizhou Medical High-tech Zone.
Jietaisi is a new product that has got the green light from the NMPA. [Photo/Taizhou Medical High-tech Zone via WeChat weigg6666]
The kit adopts a non-invasive testing method and helps in the prevention and treatment of primary hepatocellular carcinoma.
Clinical data is reported to show that Jietaisi's sensitivity and specificity in detecting liver cancer reached 88.54 percent and 95.21 percent respectively, with both attaining the leading global level.
It's understood that it can significantly improve the detection rate in early patients, effectively fill the clinical gap and potentially bring revolutionary changes to the auxiliary diagnosis of tumors.
Founded in 2014, SysDiagno Biotech is a biopharma group focusing on the research and production of IVD reagents and instruments with applied glycomics as its core field.
To date, the company has conducted long-term exploration and practiced extensively in the field of glycomics.